{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-038015","form_type":"8-K","ticker":"SCYX","cik":"0001178253","company_name":"SCYNEXIS INC","filed_at":"2024-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.575081+00:00","generated_at":"2026-06-04T05:47:15.524626+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"SCYNEXIS reports FY2023 net income of $67M, driven by $130M GSK license revenue; product revenue down 80%","bullets":["Net income of $67.0M ($1.40 basic EPS) vs net loss of $62.8M in FY2022; license revenue of $139M vs $103K prior year.","BREXAFEMME net product revenue fell to $1.0M (from $5.0M); cost of product revenue $15.6M including $14.6M inventory impairment from beta-lactam cross-contamination.","Cash, equivalents and investments $98.0M at Dec 31, 2023 (up from $73.5M); cash runway >2 years.","GSK deal total potential value revised to $448M (from $593M); final study reports due H1 2024 trigger $10M milestone payment.","SCY-247 IND-enabling activities advancing; Phase I initiation expected H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-038015","json":"https://secwatch.observer/filing/0000950170-24-038015.json","markdown":"https://secwatch.observer/filing/0000950170-24-038015.md","text":"https://secwatch.observer/filing/0000950170-24-038015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178253/000095017024038015/0000950170-24-038015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178253/000095017024038015/scyx-20240328.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T05:47:15.524626+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fec210f40ae64595e5c82f1d8b0530bcd642e82e","claim":"SCYNEXIS INC reported the year ended December 31, 2023 results: net income $67.0 million, EPS $1.40 basic income per share.","evidence_excerpt":"Net income for the full year 2023, was $67.0 million, or $1.40 basic income per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178253/000095017024038015/0000950170-24-038015-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Net income","value":"$67.0 million"},{"label":"EPS","value":"$1.40 basic income per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}